Table 1 Comparison of general data between the two groups.
Category | Precision treatment group (\(\:\stackrel{-}{x}\) ± s) | Conventional treatment group (\(\:\stackrel{-}{x}\) ± s) | t/x2 | P | |
|---|---|---|---|---|---|
Baseline BCVA (LogMAR) | 3.27 ± 0.73 | 3.59 ± 0.82 | − 1.44 | 0.16 | |
Age(years) | 55.18 ± 11.54 | 54.48 ± 12.46 | 0.20 | 0.84 | |
Intraocular pressure (mmHg) | 13.48 ± 2.78 | 12.87 ± 2.50 | 0.82 | 0.42 | |
Onset time of disease(days) | 15.05 ± 17.91 | 13.00 ± 6.41 | 0.55 | 0.58 | |
Intravitreal injections frequency (times) | 2.18 ± 0.39 | 2.85 ± 0.77 | − 3.70 | 0.002* | |
Retinal necrosis lesion zonation | 1.58 | 0.45 | |||
Zone I | 2/22(8.6%) | 6/27(22.2%) | |||
Zone II | 6/22(27.3%) | 7/27(25.9%) | |||
Zone III | 14/22(63.6%) | 14/27(51.9%) | |||
The number of quadrants involved by necrotic lesions | 0.57 | 0.90 | |||
One quadrant | 3/27(11.1%) | ||||
Two quadrants | 9/27(33.3%) | ||||
Three quadrants | 5/27(18.5%) | ||||
Four quadrants | 10/27(37.0%) | ||||
Degree of vitreous opacity | 0.1 | 0.75 | |||
Mild | 14/22(63.6%) | 16/27(59.3%) | |||
Severe | 8/22(36.4%) | 11/27(40.7%) | |||
